Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2134 • ACR Convergence 2022
Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
Richard Warren¹, Howard Sofen², Shinichi Imafuku³, Jacek C. Szepietowski⁴, Andrew Blauvelt⁵, Lynda Spelman⁶, Jessica Toms⁷, Alex Buck⁸, Subhashis Banerjee⁷ and Alan Menter⁹, ¹The University of Manchester, Manchester, United Kingdom, ²UCLA School of Medicine, Los Angeles, CA, ³Fukuoka University Hospital, Fukuoka, Japan, ⁴Wroclaw Medical University, Wroclaw, Poland, ⁵Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁶Veracity Clinical Research, Woolloongabba, Australia, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb; Cytel Inc, Princeton, ⁹Baylor University Medical Center, Dallas, TX
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signalling of key cytokines (eg, IL-23 and Type I IFN) involved in the pathogenesis…
Abstract Number: 2151 • ACR Convergence 2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Kurt de Vlam¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowinska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Frank Behrens¹², ¹University Hospitals Leuven, Leuven, Belgium, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement.…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 1018 • ACR Convergence 2022
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
Dafna Gladman¹, Laura Coates², Laure Gossec³, Jacob Aelion⁴, Jitendra Vasandani⁵, Sue Cheng⁶, Lihua Tang⁶, Shauna Jardon⁷, Sven Richter⁶ and Philip J Mease⁸, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Sorbonne Université, Paris, France, ⁴West Tennessee Research Institute, Jackson, TN, ⁵West Texas Clinical Research, Lubbock, TX, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Gilbert, AZ, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality…
Abstract Number: 1045 • ACR Convergence 2022
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used…
Abstract Number: 1268 • ACR Convergence 2022
Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
William Tillett¹, Laura Coates², Mitsumasa Kishimoto³, Arathi Setty⁴, Tianming Gao⁵, Ralph Lippe⁶ and Philip Helliwell⁷, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Kyorin University School of Medicine, Yokohama, Japan, ⁴AbbVie, Inc., Staten Island, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures using 3-visual analog scale (VAS; physician's global assessment, patient's global assessment, and skin) or 4-VAS (physician's global assessment, joints, skin, and pain)…
Abstract Number: 1504 • ACR Convergence 2022
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Alexis Ogdie¹, Christopher Ritchlin², Priscila Nakasato³, Ran Liu⁴, Christian Kaufmann⁴, Byron Padilla⁵ and Laure Gossec⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³AbbVie Inc, Toronto, ON, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Sorbonne Université, Paris, France
Background/Purpose: PsA is a systemic disease involving multiple domains. Peripheral joints are frequently affected, and patients often initially present with asymmetrical oligoarthritis (2-4 swollen joints).…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…
Abstract Number: 2118 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Jessica Walsh¹, Laura Coates², Philip J Mease³, Joseph Merola⁴, Peter Nash⁵, Alexis Ogdie⁶, William Tillett⁷, Paolo Gisondi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Vanessa Taieb¹¹, Damon Willems¹² and Lars Erik¹³, ¹University of Utah, Salt Lake City, UT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Colombes, France, Irigny, France, ¹¹UCB Pharma, Colombes, France, ¹²UCB Pharma, Brussels, Belgium, ¹³Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark
Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…
Abstract Number: 2135 • ACR Convergence 2022
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
James C Waddington¹, Ruoyi Zhou¹, Orla Coleman¹, Bruna Wundervald², Andrew Parnell³, Vinod Chandran⁴, Lara Fallon⁵, Douglass Chapman⁶, Remy Pollock⁷, Shibing Deng⁸, Oliver FitzGerald⁹, Stephen R Pennington¹⁰ and Philip J Mease¹¹, ¹Atturos, Dublin, Ireland, ²Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, ³Hamilton Institute, Maynooth University, Kildare, Ireland, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Canada ULC, Kirkland QC, Canada, ⁸Pfizer Inc, Waterford, MI, ⁹Conway Institute, University College Dublin, Dublin, Ireland, ¹⁰Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
Abstract Number: 2152 • ACR Convergence 2022
Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
Nicoletta Luciano¹, Elisa Barone², Enrico Brunetta¹, Maria De Santis³, Angela Ceribelli⁴, Marta Caprioli⁵, Giacomo Maria Guidelli¹, Arianna Sonaglia¹, Daniela Renna⁶, Francesca Motta⁷, Natasa Isailovic⁷, Matteo Vecellio³ and Carlo Selmi⁸, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Lombardia, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, ⁷Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Italy, ⁸Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy
Background/Purpose: The management of patients with psoriasis and psoriatic artrhitis (PsA) has been recently enriched and has thus become more challenging by the wide armamentarium…
Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Joseph Merola¹, Kristina Callis-Duffin², Byron Padilla³, Cuiyong Yue⁴, Huzefa Photowala⁴, Blair Kaplan⁴ and Iain B McInnes⁵, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³AbbVie, Inc., Waukegan, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
Abstract Number: 0583 • ACR Convergence 2022
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Rei Takahashi¹, Kohei Maeda¹, Toshihiro Tanioka¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
Abstract Number: 1019 • ACR Convergence 2022
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
Alexis Ogdie¹, Joseph Merola², Roberto Ranza³, Ahmed Soliman⁴, Manish Mittal⁴, Byron Padilla⁵, Sandra Ciecinski⁶, Priscila Nakasato⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie Inc, Toronto, ON, Canada, ⁸Sorbonne Université, Paris, France
Background/Purpose: Assessment of disease activity in PsA patients is important to evaluate therapeutic response in clinical trials. Patient-reported outcomes (PROs) are evaluated to assess benefits…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].